This walkthrough covers how to conduct a Design FMEA for a medical device, how it connects to ISO 14971, what the RPN number means and where it falls short, and what a well-documented FMEA record looks like from an auditor’s perspective.

FMEA and ISO 14971: how they relate

ISO 14971:2019 is the international standard for risk management of medical devices, recognized by FDA under QMSR and required by EU MDR. It defines a systematic process for identifying hazards, estimating and evaluating risk, implementing risk controls, and monitoring residual risk across the product lifecycle.

FMEA is one of several risk analysis techniques that ISO/TR 24971:2020 — the technical report supporting ISO 14971 — describes as appropriate tools for medical device risk analysis. Other methods include fault tree analysis (FTA) and hazard analysis and critical control points (HACCP). FMEA is widely used because it is structured, scalable, and produces a record format that integrates well with design documentation.

The relationship between FMEA and ISO 14971 is methodological, not equivalent. FMEA is a tool for risk identification and analysis. ISO 14971 is the framework that tells you what to do with what FMEA finds — including how to evaluate risk against acceptability criteria, how to implement controls, how to verify controls worked, and how to document the entire chain. An FMEA without an ISO 14971-compliant risk management file around it does not satisfy regulatory requirements.

Types of FMEA used in medical device development

Three types of FMEA appear most often in medical device QMS documentation:

Design FMEA (dFMEA)

Analyzes potential failure modes in the device design itself — materials, components, interfaces, functional requirements — and evaluates how those failures could affect patient safety or device performance. Conducted during design development, before design freeze.

Process FMEA (pFMEA)

Analyzes potential failures in the manufacturing process — assembly steps, inspection checkpoints, sterilization, packaging — and their effects on device quality and safety. Conducted before the manufacturing process is finalized and validated.

Use FMEA (uFMEA)

Sometimes called Human Factors FMEA or Use-Related Risk Analysis. Analyzes potential use errors — how users might misuse the device, fail to follow instructions, or encounter situations the design did not anticipate. Required when use error is a significant risk driver, and closely related to the usability engineering requirements of IEC 62366.

This article focuses on Design FMEA, as it is the most commonly required analysis for initial device submissions and the most frequently examined in FDA inspections and notified body audits.

Step-by-step: how to conduct a Design FMEA

Step 1: Define the scope and assemble the team

Start by defining what the FMEA covers: the device system, the specific subsystem or component level, and the design stage. A dFMEA conducted at system level will look very different from one conducted at the component level. For complex devices, both are needed.

FMEA is a team exercise. The team should include engineers from design, manufacturing, and quality — plus clinical input if the failure modes have patient contact implications. A dFMEA produced by one engineer in isolation will miss failure modes that cross functional boundaries.

Step 2: Identify functions and potential failure modes

For each element in scope, define its intended function. Then identify how it could fail to perform that function. These are failure modes. A single function can have multiple failure modes.

Be specific. “Component fails” is not a failure mode. “Luer lock connector fails to maintain watertight seal under 50 psi pressure” is a failure mode. Specificity at this step determines the quality of everything that follows.

Common failure mode sources: design verification test data, field complaint history for similar devices, literature on failure modes for the same technology, and experience from manufacturing process development.

Step 3: Determine potential effects

For each failure mode, identify the effect on the patient, user, or device performance. Effects are typically described at three levels: local effect (on the component or subsystem), system effect (on the device as a whole), and end effect (on the patient or user).

The end effect is what connects to your ISO 14971 hazardous situation analysis. Keep your language consistent between the FMEA and the risk management file — auditors look for this alignment.

Step 4: Rate severity

Assign a severity score to each failure effect. ISO 14971 uses qualitative or semi-quantitative categories: catastrophic, critical, marginal, and negligible — or numerical equivalents (commonly 1–10). Your risk management procedure should define what each severity level means in clinical terms.

Example severity criteria for a Class II implantable device:

• 10 (Catastrophic): patient death
• 8–9 (Critical): serious irreversible injury
• 5–7 (Moderate): reversible injury requiring medical intervention
• 2–4 (Minor): discomfort or temporary impairment, no medical intervention needed
• 1 (Negligible): no patient impact

Step 5: Identify causes

For each failure mode, identify the potential causes — design deficiencies, material properties, dimensional tolerances, process variation, use error. This is where root thinking begins. Each failure mode may have multiple causes, and each cause may have a different probability and different mitigation options.

Step 6: Assess occurrence (probability) before controls

Rate the likelihood of each failure cause occurring, before any controls are applied. This is the initial risk estimate. In ISO 14971 terms, this is the unmitigated probability. Use historical data, test data, field data from similar devices, or expert judgment — and document the basis for your estimate. FDA investigators ask how you arrived at probability ratings.

Step 7: List current design controls and rate detectability

Identify what design controls currently exist that would prevent the failure cause or detect it before it reaches the user. Design controls include design specifications, validation tests, inspections, and verification activities. Rate the effectiveness of these controls in detecting the failure before it causes harm.

Note: in many ISO 14971-aligned FMEA approaches used in medical devices, detectability scoring is secondary to the severity/probability risk evaluation. Some organizations use RPN; others use a two-dimensional risk matrix. Both are acceptable if your risk management procedure defines the methodology consistently.

Step 8: Calculate the Risk Priority Number (RPN) and evaluate

The traditional FMEA RPN = Severity × Occurrence × Detection. Higher RPNs indicate higher priority for risk control. However, RPN has known limitations in medical device risk management: two failure modes with very different severity levels can produce the same RPN, which can lead to under-prioritizing high-severity, low-frequency failures.

ISO 14971 requires evaluating risk using a risk acceptability matrix — defined in your risk management plan — that accounts for severity and probability together, not as a product score. Many manufacturers use RPN for prioritization within the FMEA while also applying the ISO 14971 risk matrix for formal acceptability determination. Both methods should be documented consistently.

Step 9: Identify and implement risk controls

For failure modes that exceed your risk acceptability criteria, identify risk controls. ISO 14971 prioritizes controls in this order: (1) design changes that eliminate the hazard or inherently reduce risk, (2) protective measures in the device or manufacturing process, (3) information for safety (labeling, warnings, instructions for use).

Document what control was implemented, who implemented it, and when. The dFMEA should reference the design output records where the control is documented — not just describe it abstractly.

Step 10: Re-evaluate residual risk after controls

After implementing controls, re-score the FMEA. The residual risk — the risk that remains after controls — must be evaluated against your acceptability criteria. If residual risk is still unacceptable, additional controls are required or the design must change.

ISO 14971 also requires a residual risk evaluation at the system level — summing all residual risks from individual failure modes to assess overall residual risk and whether the overall benefit-risk profile remains favorable.

Common FMEA mistakes that fail audits

Using “operator error” as a failure mode

Use error is a cause or a contributing factor, not a failure mode. “The user connects the catheter to the wrong port” is a use scenario. The failure mode is that your device design allows the wrong connection. Address the design — don’t just label it user error and accept the risk.

Not linking FMEA to the Design History File

Your FMEA is part of your design controls. It should reference — and be referenced by — design inputs, design outputs, verification and validation records, and the risk management file. Auditors look for this cross-referencing. An FMEA that exists as a standalone document not integrated into the DHF is a gap.

Severity scores that are not calibrated

If your severity scale is not defined in your risk management procedure, auditors will ask how you assigned severity scores. “Based on experience” is not sufficient. Define severity criteria explicitly, document them in your risk management plan, and apply them consistently across all products.

Not updating the FMEA after design changes

Every design change should trigger a review of the dFMEA to assess whether the change introduces new failure modes, changes probability or severity of existing modes, or affects the effectiveness of existing controls. A dFMEA that does not reflect the current design is not a current document.

Treating FMEA as complete after first pass

The dFMEA is a living document. It is updated during design verification, when manufacturing yields reveal unexpected failure modes, when field data from similar devices surfaces new hazards, and during post-market surveillance. FDA’s risk-based approach under QMSR expects risk management to continue throughout the product lifecycle — not stop at design freeze.

Managing FMEA in your QMS

FMEA records that live in spreadsheets create several problems: version control is unreliable, cross-referencing to design outputs and test records is manual, and there is no automatic notification when the FMEA needs review after a design change or adverse event.

Cloudtheapp’s risk management applications let you build and maintain your dFMEA within the same platform as your design controls, CAPA, and post-market surveillance. When a design change is proposed, the system flags linked risk records for review. When a complaint or adverse event is logged, it can be linked to the relevant FMEA failure mode — creating the closed-loop risk management record that FDA and notified bodies expect to see.

Want to see how Cloudtheapp connects design controls, FMEA, and risk management in a single compliant record? Book a demo to walk through the system with a specialist.

Summary

A Design FMEA done well is a design tool, not a compliance exercise. It forces your team to systematically ask what can go wrong, assess how bad the consequences are, evaluate what is in place to prevent it, and decide whether that is good enough. That thinking — documented and connected to your design decisions — is what regulators and auditors are looking for. The form it takes matters less than whether it actually reflects the device you built and the risk controls you implemented.

Cloudtheapp supports 60+ quality and compliance applications including risk management, design controls, CAPA, and post-market surveillance. Schedule a demo to see how regulated medical device companies use the platform to manage FMEA across the product lifecycle.

This post created by and appeared first on Cloudtheapp

FMEA (Failure Mode and Effects Analysis) is a structured, team-based method for identifying ways a product, process, or system can fail, understanding the consequences of each failure, and deciding which failures warrant action before they reach customers or regulators.

The method originated in the U.S. military in 1949 under MIL-P-1629, moved into NASA in the 1960s during the Apollo program, entered automotive production lines in the 1970s through Ford, and now sits at the center of quality and risk management requirements across FDA-regulated industries, automotive supply chains, and IEC-governed electrical systems.

For quality engineers and compliance teams, FMEA answers a specific question: where in this design or process is the risk most concentrated, and what are we going to do about it?

The Three Types of FMEA

The FMEA framework applies to different points in the product and process lifecycle. Understanding which type you need matters before you start.

Design FMEA (DFMEA) examines a product design before it goes to manufacturing. The team asks what could go wrong with each component, subassembly, or system function, and whether those failures would harm the end user, cause the device to malfunction, or create a regulatory compliance issue.

Process FMEA (PFMEA) shifts the analysis to manufacturing and assembly operations. Here, the failure modes involve process steps — incorrect torque, contaminated materials, misconfigured equipment — rather than component failures. PFMEA is where most production quality teams spend their time.

System FMEA takes a higher-level view, examining how subsystems interact and where system-level failures emerge from combinations of individual components that each function normally in isolation but produce unexpected behavior together.

Medical device manufacturers typically run DFMEA during design and development, PFMEA during process validation, and sometimes both together when design and manufacturing choices interact closely.

How Severity, Occurrence, and Detection Ratings Work

Every FMEA assigns three scores to each failure mode.

Severity (S) rates how bad the consequence would be if the failure occurred, on a scale of 1 to 10. A severity of 1 means the failure is barely noticeable. A severity of 9 or 10 means the failure causes patient harm, a regulatory violation, or loss of life. Severity addresses effect — it says nothing about likelihood.

Occurrence (O) estimates how often the failure mode is expected to happen, also on a 1-to-10 scale. Teams base this on historical data, process capability indices, or engineering judgment. An occurrence of 1 means the failure is almost impossible. A 9 or 10 means failures are likely to occur repeatedly in production.

Detection (D) rates how likely it is that existing controls will catch the failure before it reaches the customer. A low detection score (1-2) means your current controls will almost certainly catch this failure. A high detection score (8-10) means the failure will likely go undetected.

In the classic approach, these three numbers multiply together to produce a Risk Priority Number (RPN): RPN = S x O x D. RPNs range from 1 to 1,000. Teams set threshold values — often around 100-125 — and assign corrective actions to any failure mode above the threshold.

RPN vs. Action Priority: The AIAG-VDA 2019 Shift

The RPN method has a well-known flaw. A failure mode with a Severity of 10, an Occurrence of 1, and a Detection of 1 produces an RPN of just 10. Under classic FMEA, that failure mode might receive no action. But a severity of 10 means catastrophic harm. The RPN calculation can obscure the most dangerous failure modes by treating all three factors as equals.

The 2019 AIAG-VDA FMEA Handbook, produced jointly by the Automotive Industry Action Group and Verband der Automobilindustrie, addresses this directly by replacing RPN with Action Priority (AP). AP uses a structured lookup table in which Severity always comes first. Any failure mode with a Severity of 9 or 10 gets an Action Priority of High regardless of its Occurrence and Detection scores. The table then uses Occurrence and Detection as secondary modifiers to determine whether a lower-severity failure mode is High, Medium, or Low priority.

IEC 60812:2018, the general-purpose FMEA standard published by the International Electrotechnical Commission, still recommends the RPN approach but provides detailed guidance on how to score each dimension consistently and how to interpret RPN results in context. Teams working in electrical systems, medical devices outside the automotive supply chain, and general manufacturing most commonly reference IEC 60812:2018 for process structure.

For teams that still use RPN: the number alone never drives the decision. What matters is whether a failure mode warrants action, and a severity of 9-10 always does — regardless of what the multiplication produces.

ISO 14971 and What FDA Expects from Risk Management

ISO 14971:2019, "Medical Devices — Application of Risk Management to Medical Devices," is the international standard that governs risk management for medical devices. FDA recognizes it as a consensus standard and references it in the Quality Management System Regulation (QMSR).

FMEA fits within ISO 14971 as a risk analysis tool, but ISO 14971 asks for more than an FMEA spreadsheet. The standard requires a complete Risk Management File that covers:

• A risk management plan defining scope, responsibilities, and review criteria
• Risk analysis documenting identified hazards and their causes
• Risk evaluation determining which risks require reduction
• Risk controls with implementation evidence
• Evaluation of residual risk after controls are applied
• A benefit-risk determination for residual risks that cannot be reduced further
• Post-market surveillance data feeding back into the risk file

An FMEA can satisfy the risk analysis requirement inside ISO 14971, but it cannot substitute for the full file. Teams that submit only an FMEA without a risk management plan and without post-control evaluation regularly generate FDA Form 483 observations during device inspections.

Under the QMSR, which replaced the old 21 CFR Part 820 Quality System Regulation on February 2, 2026, FDA aligned its device quality requirements with ISO 13485:2016. This alignment brings ISO 14971's risk management approach directly into the FDA regulatory framework. Under QMSR, risk management is expected to run throughout the product lifecycle — design, production, post-market monitoring — rather than being treated as a pre-submission checklist item.

FDA inspection findings since the QMSR effective date have consistently flagged companies where risk management files are incomplete, where FMEAs have not been updated after design changes, and where post-market complaint data has not fed back into the risk register. The FDA's risk management guidance documents describe FMEA as appropriate for systematic failure analysis but emphasize that the output must connect to documented control decisions and post-market data loops.

Running an FMEA: The Six-Step Process

Most teams follow a structured process regardless of which standard they are working under.

Step 1: Define the scope. Determine whether this is a DFMEA, PFMEA, or System FMEA, and document what is in and out of scope. For a DFMEA, this typically means a functional block diagram of the device. For a PFMEA, it starts with a detailed process flow diagram.

Step 2: Identify failure modes. For each function or process step, ask what could go wrong. Document every potential failure mode — not just the ones the team considers likely. Teams that filter failure modes at this stage produce incomplete FMEAs that miss the failures that eventually reach customers.

Step 3: Analyze effects and causes. For each failure mode, document the effects on the user or the next process step, and identify the root cause or mechanism that could produce the failure. Vague cause statements like "operator error" or "material variation" do not support actionable controls.

Step 4: Rate Severity, Occurrence, and Detection. Apply the scoring criteria from your applicable standard consistently across the team. Rating calibration sessions at the start of a new FMEA reduce inter-rater variability and produce more defensible scores during audits.

Step 5: Prioritize and assign actions. Use RPN thresholds or the Action Priority table to identify which failure modes need action. Document the specific action, owner, and due date. An action field that reads "monitor" is a deferral, not an action.

Step 6: Verify and update. After implementing controls, re-score Occurrence and Detection. Severity rarely changes after a design fix unless the failure mode itself changed. Document the revised scores. An FMEA that still shows pre-control scores is an incomplete document.

Where FMEAs Break Down in Practice

Most FMEA problems in regulated environments come down to three patterns.

The first is treating the FMEA as a one-time submission artifact. Teams complete the analysis before design freeze, file it, and never return to it. When a change is made 18 months later, the FMEA does not reflect the current design. During a device inspection, investigators ask to see design change records alongside the FMEA. When the two do not match, that becomes an audit finding.

The second is disconnecting the FMEA from deviation CAPA records. When a failure mode identified in the FMEA actually occurs in production, the CAPA that follows should reference the FMEA entry. The root cause investigation should either confirm the FMEA's predicted cause or update it. FMEAs and CAPA systems maintained in separate, unlinked spreadsheets rarely stay synchronized.

The third is poor detection scoring. Teams routinely underestimate detection difficulty, assigning low scores to controls that are actually periodic spot checks or visual inspections. When a failure mode with a detection score of 2 escapes to the field and generates a complaint, investigators ask to see the detection control. What they often find is a quarterly audit that did not run in the quarter the failure occurred.

Managing FMEA in a QMS

Maintaining FMEA documents across design revisions, process changes, and post-market data updates requires a quality system that treats the FMEA as a living document rather than a static attachment.

This means version control for every FMEA revision, documented approvals when scores or actions change, links between FMEA records and design change requests, and automated notifications when a related CAPA opens that matches a documented failure mode.

Teams working in spreadsheets handle this through manual file management, which produces version control gaps and broken links between documents. When the same FMEA analysis lives in an electronic QMS with direct connections to design controls, change management records, and CAPA workflows, the update burden drops and the audit trail is automatic.

Cloudtheapp's FMEA application connects risk analysis directly to design controls, change management, and CAPA records within a single platform. When a design change request opens, the linked FMEA receives a notification for review. When a CAPA references a failure mode from the FMEA, the connection is documented and searchable. To see how this works in a live system, request a demo at cloudtheapp.com/demo/.

The Document That Defines Your Risk Posture

The FMEA table is the output. The analysis is the work, and the analysis requires a cross-functional team, structured facilitation, honest scoring, and a commitment to updating the file when new information arrives.

For quality engineers building or auditing a risk management program, the questions that matter: Does the FMEA reflect the current design? Do its high-priority failure modes have documented controls with implementation evidence? Does your post-market complaint data have an explicit pathway back into the risk file?

A well-maintained FMEA is among the most useful documents in a design file during a regulatory inspection. A stale one is among the most damaging.

This post created by and appeared first on Cloudtheapp

The FDA's Quality Management System Regulation (QMSR), effective February 2026, requires risk management across the entire product lifecycle. ISO 14971:2019 defines the framework for medical devices. Any eQMS you evaluate for risk management should connect your risk register to active QMS processes, support both DFMEA and PFMEA, integrate deviation and CAPA workflows, and maintain a 21 CFR Part 11-compliant audit trail on every decision.

Why Risk Management Has Become the Centerpiece of Regulatory Compliance

The FDA's QMSR, published in the Federal Register on February 2, 2024 and effective February 2, 2026, made one thing concrete: risk management is no longer confined to design controls. The new regulation, which aligns U.S. device manufacturers with ISO 13485, requires risk management practices across the entire product lifecycle. Where the old Quality System Regulation (QSR) mentioned risk mainly in the context of design controls, the QMSR brings it into every major QMS area, including supplier qualification, production, complaint handling, and post-market surveillance.

For quality teams at pharma, biotech, and medical device companies, this is a real operational shift. Risk management that used to live in a design file now needs to touch supplier qualification, CAPA, change management, and production records. Managing that breadth with spreadsheets or disconnected documents creates exactly the gaps that show up in FDA 483 observations.

The pharmaceutical quality management software market reflects this urgency. Grand View Research valued it at $1.87 billion in 2024 and projects it will reach $3.85 billion by 2030, a compound annual growth rate of 12.99%. Much of that growth traces back to companies moving risk management from paper to integrated electronic systems that can satisfy the QMSR and ISO 14971 requirements in a single audit-ready environment.

What ISO 14971 Requires

ISO 14971:2019 is the international standard for risk management of medical devices. It defines risk management as a continuous process covering hazard identification, risk estimation, risk evaluation, risk control, and post-production monitoring. The standard applies throughout the product lifecycle, referenced in FDA guidance, incorporated into the QMSR framework, and cited in EU MDR compliance reviews.

While ISO 14971 was written specifically for medical devices, the principles it establishes map directly to what pharma and biotech companies need under ICH Q9 (Quality Risk Management) and GxP environments. Both frameworks require documented rationale for risk decisions, evidence that controls are effective, and ongoing review when new information comes in.

The key point: risk management under both frameworks requires more than a one-time FMEA at product launch. It requires a living system where risks are tracked, controls are verified, and changes trigger automatic reassessment. A spreadsheet cannot do that reliably at scale, and FDA inspectors know what a static risk file looks like.

How the QMSR Changed the Risk Picture for U.S. Device Manufacturers

Under the old QSR (pre-2026), risk management requirements were concentrated in design controls. The QMSR, effective February 2026, incorporates risk management throughout every major clause of the regulation. FDA inspectors now use a six-area QMS framework that places risk at the center of their assessment approach, according to a February 2026 analysis by Ropes & Gray.

This matters for how you configure your eQMS. A risk management module that only connects to design records will leave gaps in supplier qualification, complaint handling, and production. FDA's updated inspection technique evaluates whether risk management is embedded systemically across the QMS, not whether you have a risk file for each product line.

Hogan Lovells reported in September 2025 that FDA was issuing warning letters at a rate consistent with the elevated pace established in 2024, marking a significant increase over prior years. The patterns across those letters: inadequate risk assessment procedures, missing corrective action documentation, and no evidence of systematic root cause investigation tied to the original risk event.

Six Things to Look for in Risk Management Software for Life Sciences

A risk register connected to your QMS processes

A standalone risk register is a documentation tool. What you actually need is a risk register that feeds from and into your active quality processes, including change management, CAPA, supplier qualification, and design controls. When a supplier fails an audit, that failure should trigger a risk re-evaluation automatically. When a design change is proposed, existing risk assessments for that product should surface immediately for review.

If the risk register only updates when someone manually opens it and enters data, it will be out of date within weeks.

FMEA at both product and process level

Failure Mode and Effects Analysis (FMEA) appears in ISO 14971 as a core risk estimation tool and in FDA QMSR compliance reviews as evidence of systematic hazard identification. Your eQMS should support both Design FMEA (DFMEA) for product-level risk and Process FMEA (PFMEA) for manufacturing and process risk.

Specifically, the FMEA module should calculate Risk Priority Numbers dynamically, update when process changes occur, and link failure modes back to open CAPAs. Static FMEA templates stored as documents create the same problem as paper: version control failures and no clear history of how risk scores changed over time.

Integrated deviation and CAPA management

Deviation CAPA management is where risk management meets daily operations. A deviation from a validated process is a risk event. Whether it becomes a formal CAPA depends on its severity and recurrence, but every deviation should be evaluated against your risk framework before the record closes.

Ask any eQMS vendor this specific question: when a deviation is opened, does it automatically trigger a risk assessment step, or does that require a separate manual workflow? Systems that require users to remember to connect these processes accumulate documentation gaps that are difficult to explain during an inspection.

A complete audit trail on every risk decision

FDA's 21 CFR Part 11 requirements cover electronic records and electronic signatures for systems used in regulated environments. For risk management software, this means every risk assessment, every control decision, and every risk acceptance must be traceable with a timestamped, user-attributed audit trail.

This is where many risk management tools built outside the life sciences context fall short. General-purpose risk software may log changes, but the audit trail often lacks the tamper-evidence and attribution detail that FDA expects during audits. A 21 CFR Part 11-compliant eQMS builds this into every risk record by default, with no additional configuration required.

Risk visibility across modules

Risk management in life sciences is not a single-department function. A quality event in production can carry risk implications for regulatory submissions. A supplier qualification failure has direct risk implications for the finished device. When your eQMS keeps these functions in separate modules with no data connection, risk information is technically documented but practically invisible to the people who need it.

The right eQMS gives quality directors a cross-module risk view: open risk assessments, overdue risk reviews, escalated items, and real-time risk exposure by product line or facility. Without that visibility, your team is managing risk after the fact rather than ahead of it.

Configuration without custom code

Risk management processes vary significantly between a Class III medical device company and a pharmaceutical manufacturer. A pharma company using ICH Q9 structures risk assessments differently than a device maker working through ISO 14971. Both may operate within the same parent organization.

Software that requires custom development every time a risk template or workflow needs to change creates a maintenance burden that most quality teams cannot sustain. No-code configuration tools that let your team adjust risk scoring criteria, approval workflows, and assessment templates without involving IT or a vendor professional services engagement are the practical standard to hold vendors to.

How Cloudtheapp Handles Risk Management in an Integrated eQMS

Cloudtheapp's risk management module is a native part of its eQMS, built to connect directly to open deviations, CAPA records, supplier qualification results, design controls, and change management workflows. When any of those processes generates a new record, the system can prompt a risk review based on configured triggers, without requiring users to manually initiate a separate risk process.

The platform supports FMEA at both product and process levels, with dynamic risk scoring and version-controlled assessment history. Every change to a risk record is logged in a 21 CFR Part 11-compliant audit trail with electronic signatures. Risk registers are configurable by product line, facility, or regulatory framework using Cloudtheapp's no-code designer tools.

For quality teams working through QMSR compliance or ISO 14971 documentation, the risk module gives each product a living risk file that updates as quality events occur, rather than requiring manual synchronization between a separate risk tool and the broader QMS. Cross-module analytics give quality directors real-time visibility into risk exposure across all open records.

Three Questions to Ask Before You Commit to a Platform

Before finalizing any risk management software for your organization, run three specific checks.

First, ask to see how the system handles a CAPA that requires a risk re-evaluation. Walk through the actual workflow in the demo environment. If the risk assessment is a separate step that requires the user to remember to open it, that is a documentation gap waiting to happen.

Second, ask for the validation package. Any eQMS deployed in a regulated environment needs documented validation artifacts. Vendors who cannot produce IQ/OQ/PQ documentation, or who require you to build it from scratch, are adding significant time and cost to your implementation timeline.

Third, ask how the system handles risk management across different regulatory frameworks in the same instance. If you manufacture devices for both U.S. and EU markets, your team needs ISO 14971 and FDA QMSR risk documentation in the same platform.

If you want to see how Cloudtheapp handles all three, book a demo and we will walk through the risk management module with your specific compliance environment in mind.

This post created by and appeared first on Cloudtheapp

Process Hazard Analysis (PHA) is a structured, systematic methodology used to identify, evaluate, and control hazards in processes that involve hazardous chemicals or complex operational sequences. Mandated by OSHA's Process Safety Management standard, the EPA Risk Management Program, and referenced across FDA and ICH Q9 quality frameworks, PHA is a compliance cornerstone for pharmaceutical manufacturers, medical device companies, chemical processors, and food producers. This guide covers the definition, regulatory context, major PHA methods, life sciences applications, step-by-step execution, QMS integration, and the documentation gaps that most teams overlook.

What Is Process Hazard Analysis?

Process Hazard Analysis, commonly abbreviated as PHA, is an organized effort to identify and evaluate hazards associated with chemical processes or operations. A PHA examines what can go wrong in a process, how likely it is, and what the consequences might be, then identifies safeguards that prevent or mitigate those outcomes.

PHA applies wherever hazardous materials or energies are present: pharmaceutical API synthesis, sterile fill-finish operations, chemical batch reactors, food processing lines, medical device assembly, and more.

The Regulatory Context: Why PHA Is Mandated

OSHA Process Safety Management (29 CFR 1910.119)

The Occupational Safety and Health Administration's Process Safety Management of Highly Hazardous Chemicals standard, codified at 29 CFR 1910.119, makes PHA a mandatory element of any PSM program. Under 29 CFR 1910.119(e), employers must perform an initial PHA on all covered processes and revalidate each PHA at least every five years. The standard specifies that the team must include at least one employee with process engineering expertise and one with operations experience.

EPA Risk Management Program (40 CFR Part 68)

The EPA's Risk Management Program requires facilities that handle regulated substances above threshold quantities to develop and implement a Risk Management Plan. Program 3 processes under EPA RMP must conduct a PHA equivalent to OSHA's PSM requirements.

FDA HACCP and Food Safety

The Food and Drug Administration's Hazard Analysis and Critical Control Points framework, referenced in 21 CFR Part 123 and Part 120 and more broadly through FDA Food Safety Modernization Act (FSMA) preventive controls requirements, applies PHA principles to food safety. FDA's HACCP guidance frames hazard analysis as the foundation of every food safety plan.

ICH Q9: Quality Risk Management in Pharmaceuticals

The International Council for Harmonisation's Q9(R1) guideline on Quality Risk Management, adopted by the FDA and published in May 2023, provides the overarching framework for risk management across the pharmaceutical product lifecycle. ICH Q9(R1) explicitly identifies HAZOP and FMEA as recognized risk assessment tools for pharmaceutical applications.

ISO 14971 for Medical Devices

For medical device manufacturers, ISO 14971:2019 specifies requirements for a risk management process that applies PHA principles throughout the entire device lifecycle. The standard mandates a Risk Management File that documents each identified hazard, its estimated probability and severity, the risk control measures applied, and residual risk acceptability.

Types of Process Hazard Analysis Methods

Hazard and Operability Study (HAZOP)

HAZOP is the most widely used PHA method in the chemical, pharmaceutical, and process industries. It applies standardized guide words, such as "No," "More," "Less," "Reverse," and "Other Than," to process parameters like flow, temperature, pressure, and composition. A HAZOP study is highly thorough and well-suited for complex, continuous, or semi-continuous processes such as Active Pharmaceutical Ingredient synthesis, solvent recovery, and bioreactor operations.

What-If Analysis

What-If analysis poses open-ended questions about potential process deviations or failures. Teams brainstorm scenarios and evaluate their likelihood and consequences. What-If is faster and more flexible than HAZOP and works well for simpler processes or early design stages.

Failure Modes and Effects Analysis (FMEA)

FMEA examines how individual components or process steps can fail, the effects of those failures, and their detectability. Each failure mode receives a Risk Priority Number (RPN) calculated by multiplying severity, occurrence, and detection scores. FMEA is the preferred method for medical device design risk assessment under ISO 14971 and for pharmaceutical equipment qualification.

Fault Tree Analysis (FTA)

FTA starts with a defined undesirable top event and works backward using Boolean logic to identify the combinations of equipment failures and human errors that could cause it. FTA is particularly useful when a specific high-consequence scenario needs deep analysis.

Checklist Analysis

Checklist analysis uses a predefined list of questions based on established standards, codes of practice, and prior experience. It is the fastest of the PHA methods but is limited to previously identified hazard types.

PHA in Life Sciences: Special Considerations

Pharmaceutical API Manufacturing

In pharmaceutical manufacturing, Active Pharmaceutical Ingredient production often involves flammable solvents, reactive intermediates, and highly potent compounds. HAZOP is the dominant method for API manufacturing PHA. The PHA output connects directly to process validation protocols, engineering controls specifications, and the facility's QMS risk register.

Medical Device Manufacturing and ISO 14971

Medical device manufacturers apply PHA principles at the product design level and the manufacturing process level. At the manufacturing process level, risk assessments evaluate contamination risks, process capability, and equipment-related failure modes that could compromise device safety or performance.

Food and Beverage: HACCP as PHA

For food and beverage manufacturers, HACCP functions as the industry-specific PHA framework. Every food safety plan mandated under FDA FSMA preventive controls must begin with a documented hazard analysis that systematically evaluates biological, chemical, radiological, and physical hazards at each process step.

How to Conduct a Process Hazard Analysis: Step by Step

Step 1: Define the Scope and Process Boundaries

Start by specifying which process or process section the PHA covers. Define the boundaries clearly and gather all relevant process documentation, including P&IDs, process flow diagrams, material safety data sheets, and operating procedures.

Step 2: Assemble the Right Team

A credible PHA requires multidisciplinary expertise. The core team typically includes a process engineer, an operations or production representative, a safety or EHS professional, and a facilitator trained in the chosen PHA method. Under OSHA PSM requirements, at least one team member must have experience in the specific process being analyzed.

Step 3: Identify Hazard Scenarios

Using the chosen method, the team systematically identifies hazard scenarios. Each scenario must be recorded with a description of the deviation or failure, its potential cause, its likely consequence, and the existing safeguards already in place.

Step 4: Evaluate Risk and Existing Safeguards

For each hazard scenario, the team estimates the likelihood of occurrence and the severity of the consequence, taking existing safeguards into account. The team then determines whether the existing safeguards are adequate or whether additional risk reduction measures are needed.

Step 5: Generate and Assign Recommendations

Where existing safeguards are inadequate, the team generates specific recommendations: engineering changes, administrative controls, procedural updates, or additional safeguards. Each recommendation is assigned to an owner with a target completion date.

Step 6: Document the PHA Report

The completed PHA must be thoroughly documented. The PHA report should include the methodology used, the team roster, the date of the study, all worksheets capturing each hazard scenario evaluated, the risk ranking for each scenario, existing safeguards, and all recommendations with their disposition status.

Step 7: Resolve Action Items and Revalidate

PHA is not a one-time activity. Action items must be tracked through completion. OSHA PSM requires that PHA recommendations be resolved promptly and that findings be communicated to affected workers. Revalidation is required every five years under OSHA PSM.

How PHA Outputs Feed Into Your QMS

The value of a PHA multiplies significantly when its outputs are fully integrated into the quality management system.

Risk Register

PHA-identified hazard scenarios with residual risk should be entered into the risk register. Cloudtheapp's Risk Assessments app and Enterprise Risk Management module provide a structured environment to capture, score, and track PHA-derived risks alongside product design risks, supplier risks, and operational risks in a unified register.

CAPA

When a PHA recommendation requires a process modification or a procedural change that addresses an identified hazard, that action is often appropriately managed through a Corrective and Preventive Action workflow. Cloudtheapp's Corrective and Preventive Actions app connects directly to risk assessments, enabling teams to link a CAPA directly to the PHA finding that triggered it.

Change Management

Process changes require a PHA review before implementation. This is the "Management of Change" element of OSHA PSM. Cloudtheapp's Change Management app integrates with risk assessment workflows so that every change request automatically triggers a hazard review step, ensuring no process modification bypasses safety evaluation.

Common PHA Documentation Gaps

Incomplete safeguard documentation. Teams identify hazards but fail to fully document the existing safeguards that justify their risk ranking.

Unresolved recommendations. PHA action items get generated but never formally closed with evidence of implementation.

No linkage to Management of Change. Organizations perform an initial PHA but then allow incremental process changes to accumulate without triggering PHA updates.

Inaccessible or paper-based records. PHA documentation stored in file cabinets or uncontrolled spreadsheets makes it difficult to retrieve during regulatory inspections.

Missing revalidation documentation. Many facilities perform revalidations informally without creating a documented record.

Integrating PHA Into a Modern QMS with Cloudtheapp

Cloudtheapp's AI-powered, no-code QMS platform provides the tools life sciences and manufacturing organizations need to run PHA as a living, integrated process rather than a static compliance document.

The Hazard Analysis app provides structured worksheets for recording and scoring hazard scenarios. The HACCP app supports food safety hazard analysis and critical control point documentation. The Risk Assessments and Enterprise Risk Management modules maintain a live risk register that connects PHA outputs to ongoing risk monitoring.

Because Cloudtheapp is validated to FDA 21 CFR Part 11 and compliant with ISO 13485, ISO 9001, and ISO 22001, all PHA documentation created in the platform carries the audit trail, electronic signature controls, and controlled document status that regulated industries require.

Ready to see how Cloudtheapp connects process hazard analysis to your entire quality system? Request a Demo at cloudtheapp.com to see the platform in action.

Conclusion

Process hazard analysis is one of the most consequential tools in the safety and quality professional's toolkit. It converts potential catastrophes into documented, managed risks. For life sciences and manufacturing companies, PHA sits at the intersection of OSHA process safety compliance, EPA environmental protection, FDA quality system requirements, and ISO risk management standards. Organizations that treat PHA as a living program, one that feeds directly into their QMS risk register, CAPA system, and change management workflow, are better protected, better prepared for regulatory scrutiny, and better positioned to prevent incidents before they occur.

This post created by and appeared first on Cloudtheapp

FMEA (Failure Mode and Effects Analysis) is a structured risk methodology that helps quality teams identify what can go wrong before it does. The right FMEA app automates RPN scoring, links to your risk register and CAPA system, supports electronic signatures, and is fully configurable to your regulatory context. For medical device, pharma, and manufacturing teams, the platform must also support ISO 14971, ICH Q9, and 21 CFR Part 11 compliance requirements. This guide covers FMEA types, regulatory basis, why spreadsheets fail, what to look for in FMEA software, and the questions you should put to every vendor.

What Is FMEA?

Failure mode and effects analysis is a structured, proactive methodology for identifying potential failures in a product, process, or system before they occur. Each potential failure mode is analyzed for its effects, and a Risk Priority Number (RPN) is calculated by multiplying three factors: Severity (S), Occurrence (O), and Detection (D). The result is a prioritized list of risks that guides corrective and preventive action.

The methodology originated in the U.S. military in the late 1950s and has since become a foundational risk tool across life sciences, automotive, manufacturing, aerospace, and food production. Today it functions as both a standalone risk analysis and a key input into broader risk management programs under international standards.

A well-executed FMEA helps quality teams accomplish four things:

• Identify failure modes before they reach the customer or patient
• Quantify and rank risk systematically using RPN
• Prioritize where corrective controls deliver the most value
• Build a traceable record for regulatory submissions and audits

The Three Types of FMEA: DFMEA, PFMEA, and SFMEA

Design FMEA (DFMEA)

DFMEA focuses on the product design itself. It identifies risks introduced by design choices, materials, architecture, interfaces, and intended use before a product enters manufacturing. In medical devices, DFMEA is a critical input to design controls under 21 CFR Part 820 and supports hazard analysis under ISO 14971.

Process FMEA (PFMEA)

PFMEA focuses on the manufacturing or assembly process. It identifies where the process itself could fail to produce a conforming product, addressing factors like equipment, personnel, environment, and materials.

System FMEA (SFMEA)

SFMEA takes a higher-level view, examining failures at the system or subsystem interaction level. It is used during early design phases to evaluate how components interact and where system-level failures could arise.

The Regulatory Basis for FMEA

ISO 14971 for Medical Devices

ISO 14971:2019 requires manufacturers to establish a risk management process covering risk analysis, evaluation, control, and monitoring throughout the device lifecycle. FMEA is one of the most widely used techniques to fulfill the risk analysis requirements of ISO 14971, particularly for design-phase hazard identification.

ICH Q9 for Pharmaceuticals

ICH Q9 on quality risk management explicitly lists FMEA as a recommended tool for pharmaceutical risk programs. FMEA under ICH Q9 supports decisions about process validation, change control, and deviation investigations.

AIAG-VDA for Automotive and Manufacturing

The AIAG-VDA FMEA Handbook sets the standard for the automotive industry. The 2019 edition introduced a revised seven-step approach and updated Severity, Occurrence, and Detection tables.

FDA 21 CFR Part 820 and 21 CFR Part 11

FDA regulations require medical device manufacturers to document risk analysis as part of their design controls. Electronic FMEA records must comply with 21 CFR Part 11 for electronic records and signatures, which requires audit trails, access controls, and validated software.

Why Spreadsheets Fail for FMEA Management

No Version Control or Audit Trail

Spreadsheets circulate by email, and version history is unreliable at best. The absence of a tamper-evident audit trail is a direct noncompliance risk under 21 CFR Part 11.

Manual RPN Calculation Creates Error Risk

Every RPN score depends on three manually entered values. Across dozens or hundreds of failure modes, the risk of calculation errors, inconsistent scoring scales, or stale values is significant.

Isolation from CAPA and Deviations

A FMEA that lives in a spreadsheet is isolated from the rest of the quality system. When a corrective action resolves a failure mode, the FMEA requires a manual update. These gaps create traceability failures that surface during audits.

Electronic Signature Gaps

FDA-regulated environments require electronic signatures that meet 21 CFR Part 11 requirements. Spreadsheets cannot provide compliant e-signatures.

What to Look for in an FMEA App

1. Automated RPN Calculation with Configurable Risk Matrices

The software should calculate RPN automatically from Severity, Occurrence, and Detection inputs and alert the team when scores exceed defined thresholds. The risk matrix should be configurable without code to match your regulatory context.

2. Direct Integration with the Risk Register

FMEA findings should flow directly into your organization's risk register. When your FMEA app links failure modes to a live risk register, your organization's risk profile stays current as new FMEAs are completed, controls are implemented, and residual risk is reassessed.

3. CAPA and Deviation Integration

Every high-RPN failure mode should be able to generate a corrective and preventive action directly from the FMEA record, with a traceable link between both records. Root cause investigation is far more effective when FMEA data is integrated into the same system.

4. Electronic Signatures Compliant with 21 CFR Part 11

FMEA reviews, approvals, and closures require signatures that meet 21 CFR Part 11 requirements. Every action on every record should be logged with a timestamp and user identity.

5. Design Controls Integration for Medical Device Teams

For medical device manufacturers, the FMEA is a design control document. The software should link FMEA records to design inputs, design outputs, and verification and validation activities.

6. A Validated Platform with Compliance Documentation

A purpose-built FMEA app for regulated industries should include a full validation package: IQ, OQ, and PQ documentation for each software version.

7. Support for DFMEA, PFMEA, and SFMEA Workflows

The tool should support all three FMEA types within a single environment, with form templates appropriate to each methodology.

8. Role-Based Access and Collaborative Review

The platform should support role-based access so that design engineers, QA reviewers, and management approvers each work on the records relevant to their function.

Questions to Ask FMEA Software Vendors

1. Is the platform FDA-validated and does it include IQ/OQ/PQ documentation for each platform update?
2. Does the risk matrix support custom scoring scales aligned to ISO 14971, AIAG-VDA, and ICH Q9?
3. How does the FMEA module connect to CAPA, deviations, and the risk register within the same system?
4. Are electronic signatures compliant with 21 CFR Part 11, including audit trail and unique credentials?
5. How are FMEA records linked to design controls and the Design History File?
6. Can risk matrix thresholds and scoring scales be configured without code or custom development?

How Cloudtheapp Handles FMEA in a Validated Quality System

Cloudtheapp includes a dedicated FMEA application available in the Cloudtheapp Store, built for regulated industries and designed to work alongside your full quality program.

The FMEA app connects directly to Risk Assessments, CAPA, Deviations, and Design Controls within the same platform. When a high-RPN failure mode requires action, a CAPA record can be initiated from the FMEA entry, and both records maintain a traceable link. The risk register stays current as FMEAs are completed and reviewed, without manual reconciliation between separate tools.

The risk matrix in Cloudtheapp is fully configurable without code. Medical device teams working under ISO 14971 can define their own severity and probability scales, acceptability criteria, and RPN thresholds directly in the platform using no-code designer tools.

Electronic signatures on all FMEA records meet 21 CFR Part 11 requirements, with a complete, tamper-evident audit trail on every entry, edit, and approval. The Cloudtheapp platform is validated under FDA 21 CFR Part 820, ISO 13485, and ISO 9001, and a full validation package is provided with every platform update.

If your team is still managing FMEA in spreadsheets, or using a standalone tool that does not connect to your QMS, Cloudtheapp is built to solve that problem.

Request a demo at cloudtheapp.com to see how the FMEA app works inside a fully integrated, validated quality management system.

This post created by and appeared first on Cloudtheapp